Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel El Fassi

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Frontiers in Immunology|August 22, 2022
Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppressionAna Micaela Carnaz Simões, Morten Orebo Holmström, Pia Aehnlich, et al.
Journal of Fungi (Basel, Switzerland)|November 11, 2020
Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention AnalysisMalene Risum, Jannik Helweg-Larsen, Søren Lykke Petersen, et al.
Ugeskrift for Laeger|October 28, 2021
[Elevated blood cell counts and vascular disease with the myeloproliferative neoplasms as model diseases]Hans Carl Hasselbalch, Trine Alma Knudsen, Anders Lindholm Sørensen, et al.
Cancer Medicine|June 23, 2018
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosisStine Ulrik Mikkelsen, Lasse Kjaer, Mads Emil Bjørn, et al.
Blood Advances|June 17, 2021
A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2Anne Louise Tølbøll Sørensen, Magalie Rolland, Jacob Hartmann, et al.
Frontiers in Oncology|June 5, 2023
The multidisciplinary approach to eosinophiliaGunhild Nynke Thomsen, Mette Niemann Christoffersen, Hanne Merete Lindegaard, et al.
Frontiers in Oncology|March 15, 2021
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With <i>CALR</i>-Mutant Chronic Myeloproliferative NeoplasmsJacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Jørgensen, et al.
Haematologica|October 15, 2020
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II studyAnders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, et al.
Orphanet Journal of Rare Diseases|July 31, 2024
DAHEAN: A Danish nationwide study ensuring quality assurance through real-world data for suspected hereditary anemia patientsAndreas Glenthøj, Andreas Ørslev Rasmussen, Selma Kofoed Bendtsen, et al.
Blood Advances|September 10, 2021
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responsesTrine Alma Knudsen, Vibe Skov, Kristen Stevenson, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Frontiers in Immunology|August 22, 2022
Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppressionAna Micaela Carnaz Simões, Morten Orebo Holmström, Pia Aehnlich, et al.
Journal of Fungi (Basel, Switzerland)|November 11, 2020
Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention AnalysisMalene Risum, Jannik Helweg-Larsen, Søren Lykke Petersen, et al.
Ugeskrift for Laeger|October 28, 2021
[Elevated blood cell counts and vascular disease with the myeloproliferative neoplasms as model diseases]Hans Carl Hasselbalch, Trine Alma Knudsen, Anders Lindholm Sørensen, et al.
Cancer Medicine|June 23, 2018
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosisStine Ulrik Mikkelsen, Lasse Kjaer, Mads Emil Bjørn, et al.
Blood Advances|June 17, 2021
A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2Anne Louise Tølbøll Sørensen, Magalie Rolland, Jacob Hartmann, et al.
Frontiers in Oncology|June 5, 2023
The multidisciplinary approach to eosinophiliaGunhild Nynke Thomsen, Mette Niemann Christoffersen, Hanne Merete Lindegaard, et al.
Frontiers in Oncology|March 15, 2021
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With <i>CALR</i>-Mutant Chronic Myeloproliferative NeoplasmsJacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Jørgensen, et al.
Haematologica|October 15, 2020
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II studyAnders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, et al.
Orphanet Journal of Rare Diseases|July 31, 2024
DAHEAN: A Danish nationwide study ensuring quality assurance through real-world data for suspected hereditary anemia patientsAndreas Glenthøj, Andreas Ørslev Rasmussen, Selma Kofoed Bendtsen, et al.
Blood Advances|September 10, 2021
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responsesTrine Alma Knudsen, Vibe Skov, Kristen Stevenson, et al.
Pageof 5